Detalles de la búsqueda
1.
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.
Int J Mol Sci
; 24(8)2023 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37108738
2.
Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.
Eur Respir J
; 51(3)2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545318
3.
Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.
Ann Surg Oncol
; 25(4): 1069-1078, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29362963
4.
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Lancet
; 387(10026): 1415-1426, 2016 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26777916
5.
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.
Eur Respir J
; 50(2)2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28798090
6.
Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery.
Br J Cancer
; 115(3): 346-53, 2016 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-27336603
7.
Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.
Future Oncol
; 12(1): 59-70, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26616848
8.
Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Br J Cancer
; 113(8): 1206-15, 2015 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26372703
9.
Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer.
Biomedicines
; 11(7)2023 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37509464
10.
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.
Cancers (Basel)
; 14(5)2022 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35267628
11.
Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.
Cancers (Basel)
; 13(19)2021 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34638411
12.
Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study.
PLoS One
; 15(7): e0234387, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32609781
13.
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
J Thorac Oncol
; 15(1): 120-124, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31605799
14.
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes.
JTO Clin Res Rep
; 1(3): 100052, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34589947
15.
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
Lung Cancer
; 140: 19-26, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31841714
16.
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
Clin Lung Cancer
; 20(3): 222-230, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30679079
17.
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
J Thorac Oncol
; 14(8): 1400-1407, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31108248
18.
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
Eur J Cancer
; 116: 86-97, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31181537
19.
KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.
Clin Lung Cancer
; 19(6): e919-e931, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30217639
20.
SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients.
Cancer Med
; 7(7): 3278-3291, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29845746